Vident Advisory’s ADMA Biologics ADMA Stock Holding History

Vident Advisory’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359K	Sell	42,922 -77,913	-64%	-$710K	﹤0.01%	1528
2026 Q1	$1.09M	Sell	120,835 -149,657	-55%	-$2.36M	0.01%	844
2025 Q4	$4.93M	Buy	270,492 +52,687	+24%	+$888K	0.04%	333
2025 Q3	$3.19M	Buy	217,805 +75,056	+53%	+$1.29M	0.03%	425
2025 Q2	$2.6M	Buy	142,749 +4,874	+4%	+$99.4K	0.03%	434
2025 Q1	$2.74M	Buy	+137,875	New	+$2.38M	0.04%	375

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vident Advisory's ADMA Position: Q2 2026 in Review

Vident Advisory reduced its ADMA Biologics (ADMA) stake by 64% in Q2 2026, selling an estimated $710K and leaving 42,922 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Vident Advisory first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.93M in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Vident Advisory held 42,922 shares of ADMA Biologics worth $359K as of Q2 2026.
Vident Advisory sold 77,913 ADMA Biologics shares in Q2 2026, an estimated $710K.
ADMA Biologics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1528 holding.
Vident Advisory first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
Vident Advisory's ADMA Biologics position peaked at $4.93M in Q4 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.